CJC-1295 and Ipamorelin produce synergistic growth hormone release by converging on the pituitary gland's somatotroph cells from 2 independent receptor systems — the GHRH receptor and the ghrelin receptor (GHS-R1a). In a 2006 randomized, placebo-controlled human trial, CJC-1295 alone produced dose-dependent GH increases of 2–10 fold and IGF-1 increases of 1.5–3 fold in healthy adults, sustained for up to 11 days after a single injection. Adding Ipamorelin — a selective growth hormone releasing peptide that triggers rapid GH pulses without elevating cortisol, ACTH, or prolactin — amplifies those pulses through a completely separate receptor pathway.
This makes the CJC-1295 + Ipamorelin combination the most evidence-backed peptide stack in the community. The individual compounds have published human pharmacology data, and the GHRH + GHRP synergy mechanism has been validated in separate controlled human studies. The critical qualification: the specific combination protocol as used in community practice — 100–300 mcg of each, injected daily before bed on an empty stomach — has never been studied in a published clinical trial.
This guide covers the dual-receptor synergy mechanism, why this combination is preferred over alternatives, what the human evidence actually shows, community dosing protocols, expected timelines, cycling requirements, side effects, and quality verification for both compounds. For the full science on each compound individually, see the CJC-1295 science deep-dive and the Ipamorelin science deep-dive. For the CJC-1295 DAC vs no-DAC comparison, see the dedicated disambiguation article. For the broader context of peptide combinations, see the peptide stacking guide. For the full muscle growth peptide category, see the pillar page.
How Do CJC-1295 and Ipamorelin Work Together?
CJC-1295 and Ipamorelin produce synergistic growth hormone release by converging on the pituitary's somatotroph cells from 2 independent receptor systems — the GHRH receptor and the ghrelin receptor (GHS-R1a) — generating GH pulse amplitudes significantly greater than either compound alone, a mechanism validated in published human pharmacology studies.
CJC-1295 without DAC (also known as Mod GRF 1-29 or Modified GRF) is a synthetic analog of growth hormone releasing hormone (GHRH). It binds to the GHRH receptor on pituitary somatotroph cells and stimulates them to produce and release growth hormone. In the Teichman et al. 2006 study published in the Journal of Clinical Endocrinology & Metabolism, subcutaneous administration of CJC-1295 in healthy adults (ages 21–61) produced dose-dependent GH concentration increases of 2–10 fold sustained for 6 or more days, and IGF-1 increases of 1.5–3 fold sustained for 9–11 days. The estimated half-life was 5.8–8.1 days, and there was evidence of a cumulative effect after multiple doses. No serious adverse events were reported.
Ipamorelin is a selective growth hormone releasing peptide (GHRP) that binds to the ghrelin receptor (GHS-R1a) on the same somatotroph cells — but through a completely different receptor. It triggers a rapid, potent GH pulse. Crucially, published Ipamorelin selectivity research demonstrates that it releases growth hormone without elevating ACTH, cortisol, or prolactin — a selectivity profile that distinguishes it from every other GHRP in its class and is the primary reason it is preferred for combination protocols.
The synergy mechanism operates on two levels. First, when a GHRH analog and a GHRP are co-administered, they converge on somatotroph cells from 2 independent receptor systems simultaneously. Published GHRH + GHRP combination studies in humans demonstrate that this dual-receptor activation produces GH pulse amplitudes significantly greater than either class alone — this is the best-validated synergy mechanism in the peptide stacking space.
Second, Ipamorelin partially overcomes somatostatin suppression. Somatostatin is the body's GH-inhibiting hormone — it acts as a brake on GH release from the pituitary. When Ipamorelin activates the ghrelin receptor, it reduces the inhibitory effect of somatostatin, which means CJC-1295's signal to "release growth hormone" encounters less resistance. The result is the "pulse and sustain" model: Ipamorelin provides the fast, strong GH pulse (onset within minutes of injection), while CJC-1295 extends the duration of that pulse and sustains an elevated GH baseline. Together, they approximate natural pulsatile GH secretion more closely than either compound alone.
Why This Combination Instead of Other GH Secretagogues?
CJC-1295 + Ipamorelin is preferred over alternative GH secretagogue combinations because Ipamorelin is the most selective GHRP available — it releases growth hormone without elevating cortisol, prolactin, or appetite — which makes the stack's side effect profile significantly cleaner than combinations using GHRP-2, GHRP-6, or Hexarelin.
GHRP-2 produces stronger GH release than Ipamorelin per dose but significantly elevates cortisol and prolactin. Elevated cortisol opposes the body composition benefits that GH secretagogues are used for — it promotes fat storage, catabolizes muscle, and disrupts sleep. Elevated prolactin can suppress libido and cause gynecomastia in men. GHRP-2 also increases appetite more than Ipamorelin, which is counterproductive for users targeting fat loss.
GHRP-6 activates the ghrelin receptor with even less selectivity than GHRP-2. Its most prominent non-GH effect is intense appetite stimulation — useful for underweight individuals who need caloric drive, but problematic for the majority of users pursuing body recomposition. GHRP-6 also elevates cortisol and prolactin to a degree that many practitioners consider unacceptable for sustained protocols.
Hexarelin is the most potent GH secretagogue in the GHRP class — it produces the highest GH pulse amplitude. However, it demonstrates rapid receptor desensitization (loss of efficacy within 4–8 weeks of continuous use), significantly elevates cortisol and prolactin, and is generally considered unsuitable for the 8–12 week protocols that most GH optimization goals require.
Sermorelin is an older GHRH analog that works through the same GHRH receptor as CJC-1295 but with a shorter half-life and generally lower potency per dose. It is a legitimate alternative for the GHRH component of the stack, but most community protocols have migrated to CJC-1295 (no DAC) for the sustained GH signaling it provides.
Tesamorelin is the only GHRH analog with FDA approval — specifically for reduction of excess abdominal fat in HIV-associated lipodystrophy. It has Phase III clinical trial data, but it is available only by prescription for that indication and priced accordingly. It occupies a different clinical tier than the research-grade secretagogues discussed here.
The CJC-1295 + Ipamorelin combination wins on the selectivity-to-efficacy ratio: a strong synergistic GH pulse with the cleanest side effect profile of any GHRH + GHRP pairing currently available. This is why it has become the default GH secretagogue stack across both the biohacking community and supervised clinical peptide programs.
What Does the Evidence Actually Show?
CJC-1295 is the GH secretagogue with the strongest published human data — a 2006 randomized, placebo-controlled trial in healthy adults demonstrated dose-dependent GH increases of 2–10 fold and IGF-1 increases of 1.5–3 fold sustained for up to 11 days — and the GHRH + GHRP synergy mechanism has been validated in separate human studies, making this the most evidence-backed peptide stack in the community, though the specific combination protocol has never been studied.
CJC-1295 human data: The Teichman et al. 2006 study (Journal of Clinical Endocrinology & Metabolism) consisted of 2 randomized, placebo-controlled, double-blind, ascending-dose trials enrolling healthy adults ages 21–61. Single-dose administration produced sustained GH and IGF-1 elevations. Multiple-dose administration showed a cumulative effect with mean IGF-1 remaining above baseline for up to 28 days. The half-life was estimated at 5.8–8.1 days. No serious adverse events were reported. The study concluded that CJC-1295 supports "potential utility as a therapeutic agent."
Ipamorelin human data: Ipamorelin has been studied in a Phase 2 clinical trial for postoperative ileus (bowel recovery after surgery), demonstrating dose-dependent GH release and acceptable safety/tolerability in a surgical patient population. Separate pharmacology studies published in the European Journal of Endocrinology confirmed Ipamorelin's selective GH release without ACTH, cortisol, or prolactin elevation — establishing its selectivity profile in humans.
GHRH + GHRP synergy human data: Multiple published studies using various GHRH + GHRP pairings (not always CJC-1295 + Ipamorelin specifically, but the same receptor-class combination) demonstrate that co-administration of a GHRH analog with a GHRP produces synergistic GH pulse amplitudes in humans. This dual-receptor synergy is the strongest mechanistic claim in the peptide stacking space — it has been replicated across studies and is consistent with known somatotroph receptor biology.
The specific community protocol: No published study has examined CJC-1295 (no DAC) + Ipamorelin at 100–300 mcg of each, administered daily pre-sleep in a fasted state, over 8–12 weeks, measuring body composition, recovery, sleep, or anti-aging endpoints in healthy adults. The body composition claims (fat loss, lean mass retention, improved sleep, enhanced recovery) are extrapolated from GH/IGF-1 physiology and from community/practitioner observation — not from RCT data using this protocol.
This is the most evidence-backed peptide stack available, but "most evidence-backed" is relative. The human data validates the individual compounds and the synergy mechanism. The specific protocol, endpoints, and long-term outcomes remain unstudied.
What Does a Typical CJC-1295 + Ipamorelin Protocol Look Like?
The standard CJC-1295 + Ipamorelin protocol uses 100–300 mcg of each compound, injected subcutaneously once daily before bed on an empty stomach — and the fasted timing is not optional, because insulin from food directly suppresses the GH release that the entire stack is designed to produce.
These are community and practitioner-derived protocols, not FDA-approved clinical guidelines. No standardized dosing has been established through regulatory review.
Dosing: 100–300 mcg of CJC-1295 (no DAC) plus 100–300 mcg of Ipamorelin per injection. The most common community dose is 200–300 mcg of each. Both compounds are measured in micrograms (mcg).
Timing: Before bed, at least 2 hours after your last meal. Growth hormone is predominantly released during deep slow-wave sleep, and the stack is designed to amplify this natural nocturnal pulse. Food — especially carbohydrates and protein — raises insulin, which directly inhibits GH release from the pituitary. Fasted administration is foundational to this protocol's efficacy, not merely a preference.
Frequency: Once daily is the standard approach. Some aggressive protocols use twice daily (morning fasted + pre-sleep fasted) to produce 2 GH pulses per day. Some clinic protocols use a 5-day-on / 2-day-off weekly schedule to reduce cumulative receptor exposure while maintaining benefits.
Titration: Gradual dose escalation is recommended. Start at 100 mcg of each for weeks 1–2. Increase to 200 mcg by week 3. Reach 250–300 mcg by weeks 4–5 if tolerated. This allows the body to adjust to increased GH signaling without overwhelming the pituitary axis or triggering unnecessary side effects.
Injection: Subcutaneous, typically in the abdominal fat pad. Neither compound requires localized injection near a specific tissue (unlike BPC-157 for injury repair). Rotate injection sites to prevent lipodystrophy.
Protocol length: 8–12 weeks is the standard cycle. Some clinic protocols extend to 16 weeks. The most common structure is 3 months on, 1 month off (see cycling section below).
Both compounds can be drawn into the same syringe immediately before injection — they are both water-soluble with compatible pH profiles. For dose math assistance, see how to calculate peptide doses. For preparation, see reconstituting peptides step by step.
For sourcing verification: where to buy CJC-1295 and where to buy Ipamorelin.
Reconstitution Math
CJC-1295 (5 mg vial): Add 2 mL bacteriostatic water. Resulting concentration: 2,500 mcg/mL. For a 250 mcg dose, draw 0.10 mL (10 units on a standard insulin syringe). For a 300 mcg dose, draw 0.12 mL (12 units).
Ipamorelin (5 mg vial): Add 2 mL bacteriostatic water. Resulting concentration: 2,500 mcg/mL. For a 250 mcg dose, draw 0.10 mL (10 units). For a 300 mcg dose, draw 0.12 mL (12 units).
Pre-blended vials (typically 10 mg total: 5 mg CJC-1295 + 5 mg Ipamorelin): Add 2 mL bacteriostatic water. Resulting concentration: 5 mg/mL total (2,500 mcg/mL of each compound). For 250 mcg of each, draw 0.10 mL (10 units). Pre-blended vials are convenient but reduce dose flexibility — you cannot independently adjust the dose of each compound.
Direct bacteriostatic water against the vial wall, not onto the powder. Gently swirl — never shake. Verify the solution is clear; discard if cloudy. Label each vial with the compound name, date, and concentration. Store refrigerated at 2–8°C.
What Results to Expect and When
Improved sleep quality — deeper slow-wave sleep, more vivid dreams, and feeling more rested upon waking — is typically the first noticeable effect of the CJC-1295 + Ipamorelin stack, usually reported within 1–2 weeks, while measurable body composition changes (fat loss, lean mass, skin quality) generally require 4–8 weeks of consistent use.
Weeks 1–2: Sleep improvement is the most commonly reported early effect. GH is predominantly released during deep slow-wave sleep, and enhanced GH pulsatility directly improves this sleep stage. Users frequently describe falling asleep faster, sleeping more deeply, and waking feeling more rested. Vivid or unusually detailed dreams are also common — this is a recognized effect of enhanced GH-mediated sleep architecture.
Weeks 2–4: Recovery between training sessions improves. Reduced delayed onset muscle soreness (DOMS) after resistance training. Some users report increased energy levels and improved mood stability. Water retention may peak during this period — a downstream effect of elevated GH, not fat gain. Facial flushing immediately after injection is common and transient (typically subsides within 15–20 minutes).
Weeks 4–8: Body composition changes become visible. Reduced body fat — particularly abdominal fat — as IGF-1 elevation enhances fat metabolism. Improved lean muscle definition, especially when combined with consistent resistance training and adequate protein intake (1.6–2.2 g/kg/day). Skin elasticity improvement as GH stimulates collagen synthesis.
Weeks 8–12: Continued body recomposition. Hair and nail growth rate increases. Skin quality improvement becomes more pronounced. GH/IGF-1 axis reaches full optimization at steady state. Water retention typically normalizes by this point as the body adapts.
These timelines are from practitioner observation and community experience, not from controlled trials measuring specific endpoints with this protocol. The peptides support GH release — they do not replace the training stimulus, nutritional foundation, or sleep quality that determine how that GH is used.
Side Effects, Safety & Who Should Not Use This Stack
The most common side effects of the CJC-1295 + Ipamorelin stack — water retention, facial flushing, and mild headache — are downstream effects of elevated growth hormone, not direct toxicity from the peptides themselves, and most users report these effects peaking in weeks 2–4 before subsiding as the body adjusts.
Common side effects (generally mild and transient): water retention (puffy face, mild swelling in hands and feet — responds to sodium reduction), facial flushing immediately post-injection (vasodilation — resolves within 15–20 minutes), mild headache in the first 1–2 weeks, injection site redness or irritation, temporary fatigue, mildly increased appetite (significantly less than with GHRP-6), and vivid or occasionally disturbing dreams (GH effect on sleep architecture).
Less common but clinically relevant: insulin sensitivity changes — growth hormone elevates blood glucose, and sustained GH elevation can reduce insulin sensitivity. This is dose-dependent and particularly relevant for individuals with prediabetes, type 2 diabetes, or metabolic syndrome. Published research on GH and insulin resistance documents this relationship. Carpal tunnel-like symptoms (tingling or numbness in hands) can occur from fluid retention compressing the median nerve — this is dose-dependent and resolves with dose reduction or protocol completion. Joint aches from fluid retention are occasionally reported but are not structural.
Contraindications — who should NOT use this stack:
Active cancer or history of hormone-sensitive cancer. Elevated GH and IGF-1 may promote tumor growth. Cancer survivors or those with active malignancy should avoid all GH secretagogues. This applies to both CJC-1295 and Ipamorelin.
Diabetes or significant insulin resistance without monitoring. GH elevates blood glucose. Users with metabolic concerns should only use GH secretagogues under medical supervision with regular glucose and insulin monitoring.
Pregnancy or breastfeeding. Insufficient safety data exists for either compound during pregnancy or lactation.
Important: this stack does NOT suppress endogenous testosterone production. CJC-1295 and Ipamorelin operate on the GH axis (hypothalamus → pituitary → GH → IGF-1), not the HPTA (hypothalamic-pituitary-testicular axis). No post-cycle therapy (PCT) is needed. This distinguishes the stack from anabolic steroids and SARMs, which do suppress testosterone.
Neither compound is FDA-approved for any indication. Both are classified as growth hormone secretagogues on the WADA Prohibited List and are banned in all competitive sports, both in-competition and out-of-competition. For the legal status by country, see the regulatory guide.
Do You Need to Cycle This Stack?
Yes — growth hormone secretagogues require cycling because both the GHRH receptor and the ghrelin receptor can downregulate with prolonged continuous stimulation, and the standard CJC-1295 + Ipamorelin cycle is 8–12 weeks on, followed by 4–6 weeks off.
Receptor downregulation is the body's adaptive response to sustained stimulation: when a receptor is continuously activated, the cell reduces its sensitivity or the number of receptors on its surface, requiring a higher dose to achieve the same effect. The clearest signal of desensitization is required dose escalation — if the same dose produces weaker effects over time (less sleep improvement, less recovery benefit), that indicates receptor adaptation. The correct response is to begin the off-cycle, not to increase the dose, which accelerates desensitization further.
Standard cycle structure: 8–12 weeks on, 4–6 weeks off. Some practitioners prefer 3 months on, 1 month off (yielding approximately 3 full cycles per year). During the off-cycle, GH levels return to your pre-protocol baseline. Some users report a noticeable decrease in sleep quality and recovery during the break — this is expected and actually confirms the stack was providing genuine effect.
5-on/2-off weekly schedule: Some clinic protocols prescribe 5 days of injection followed by 2 days off each week throughout the entire cycle. This may reduce cumulative receptor exposure without requiring a full multi-week break. The evidence for this approach over a continuous on-cycle is anecdotal.
Why this stack has better cycling tolerance than Hexarelin: Hexarelin, the most potent GHRP, shows significant receptor desensitization within 4–8 weeks even with cycling — eventually requiring longer off-periods or permanent response loss. The CJC-1295 + Ipamorelin combination maintains efficacy for 12+ weeks in most community reports, which is one of the reasons it has become the default over more potent but less sustainable alternatives.
For the broader context on cycling across peptide categories, see the peptide stacking guide.
How to Verify Quality for Both Compounds
The most common quality issue with the CJC-1295 + Ipamorelin stack is compound misidentification — vendors selling "CJC-1295" without specifying whether the product is the DAC or no-DAC version, which are different compounds with different molecular weights and different dosing protocols.
CJC-1295 without DAC (Mod GRF 1-29) and CJC-1295 with DAC are structurally different peptides. The DAC version includes a Drug Affinity Complex that binds to serum albumin, extending the half-life to 6–8 days. The no-DAC version has a half-life of approximately 30 minutes. The dosing protocols, injection frequencies, and physiological effects differ substantially. If a vendor's Certificate of Analysis (COA) does not specify which version was tested — or if the mass spectrometry result shows a molecular weight that doesn't match the expected sequence — you may be receiving a different compound than intended.
Each compound needs its own independent, batch-specific COA with HPLC purity (≥98% for research grade) and mass spectrometry identity confirmation (observed molecular weight must match the theoretical MW of the specified compound). A purity percentage without mass spec identity verification tells you the sample is clean — but not that it is the right peptide. For a complete understanding of HPLC testing methodology, see the testing guide.
Pre-blended CJC/Ipamorelin vials (typically 10 mg combined) present the same verification challenge as Wolverine Stack blends: a standard HPLC run on a blend produces combined peaks that are more difficult to attribute to individual compounds, and confirming the exact concentration of each peptide requires more complex analysis. Sourcing each compound separately with individual COAs provides the highest verification confidence.
Red flags: a vendor lists "CJC-1295" without specifying DAC or no-DAC; the COA molecular weight doesn't match the expected sequence for either version; a single COA is provided for a blend without separate identity confirmation for each component; the same COA appears across multiple batches or order dates.
Peptigrity's independent lab test database includes HPLC purity tests for both CJC-1295 and Ipamorelin across multiple vendors. The shop reviews and trust scores provide an additional verification layer. For the complete quality verification process, see how to verify peptide quality before you buy and COA red flags to watch for.
Frequently Asked Questions
Can I add BPC-157 and TB-500 to this stack?
Yes — the 4-compound protocol (BPC-157 + TB-500 + CJC-1295 + Ipamorelin) is the most commonly asked-about multi-stack combination in the peptide community. The healing peptides (BPC-157/TB-500) and the GH secretagogues (CJC-1295/Ipamorelin) operate through entirely separate receptor systems with no known pharmacological conflict. Typical timing: BPC-157 and TB-500 in the morning (healing focus, no fasting required), CJC-1295 and Ipamorelin pre-sleep on an empty stomach (GH optimization). For full combination details, see the peptide stacking guide.
Is this stack better than synthetic HGH?
Different mechanisms with different risk profiles. CJC-1295 + Ipamorelin stimulates your own pituitary gland to release endogenous growth hormone in a pulsatile, physiological pattern — it does not suppress your body's natural GH production. Synthetic HGH introduces exogenous growth hormone, which can suppress endogenous production over time and carries a different side effect profile, including potential organ growth at supraphysiological doses. The peptide stack produces a more natural GH pattern but at lower total GH levels than therapeutic HGH doses. Synthetic HGH is FDA-approved for documented GH deficiency; the peptide stack is not FDA-approved for any indication. The choice depends on the clinical goal, the desired GH level, and whether medical supervision is available.
Does this stack require PCT (post-cycle therapy)?
No. CJC-1295 and Ipamorelin do not suppress endogenous testosterone, LH, or FSH production. They operate on the GH axis (hypothalamus → pituitary → GH → liver → IGF-1), not the HPTA (hypothalamic-pituitary-testicular axis) that governs testosterone production. No post-cycle therapy is needed after discontinuing this stack. This is a fundamental difference from anabolic steroids and SARMs, which suppress testosterone and require PCT protocols.
Should I use CJC-1295 with DAC or without DAC for this stack?
Without DAC (also called Mod GRF 1-29) is the version used in the vast majority of community stacking protocols with Ipamorelin. The no-DAC version has a shorter half-life (approximately 30 minutes), which produces a more natural pulsatile GH pattern that aligns with Ipamorelin's rapid-pulse mechanism. The DAC version maintains continuously elevated GH for 6–8 days, which is less physiological, may increase water retention and insulin resistance, and does not match the "pulse and sustain" model that makes the stack effective. For the complete analysis, see the CJC-1295 DAC vs no-DAC comparison.
What blood work should I get before and during this stack?
Baseline (before starting): serum GH, IGF-1, fasting glucose, fasting insulin, HbA1c, and a comprehensive metabolic panel. These establish your pre-protocol hormonal and metabolic status.
Follow-up (at 4–8 weeks): repeat IGF-1 (the most practical marker — it reflects sustained GH activity over days, whereas GH itself has a short half-life and fluctuates throughout the day), fasting glucose and fasting insulin (to monitor for insulin sensitivity changes), and a metabolic panel. If IGF-1 has not increased meaningfully, reassess product quality, dosing accuracy, and injection timing (fasted vs. fed).
IGF-1 is your primary confirmation that the stack is producing its intended GH-axis effect. If your baseline IGF-1 is already in the upper range of normal, the marginal benefit of additional GH stimulation may be limited — and the risk of insulin resistance increases.
This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
